echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Industry: After the Spring Festival, the pharmaceutical and medical sector is expected to break out!

    Industry: After the Spring Festival, the pharmaceutical and medical sector is expected to break out!

    • Last Update: 2023-02-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    【Pharmaceutical Network Market Analysis】At present, A-shares are in the key layout stage of the year, which has attracted the attention
    of investors and institutions.
    CITIC Securities said a few days ago that it is still a good time to increase positions, and it is recommended to focus on varieties that are in the "depression" and have explosive power after the Spring Festival in the short term, and the bank recommends the layout of varieties with low positions, smooth industrial logic, high performance flexibility, and is expected to have explosive power after the Spring Festival long holiday
    .
    With the aging of the population, the upgrading of consumption levels, and the enhancement of people's health awareness in the post-epidemic era, the pharmaceutical and medical industry has long-term development space
    .
    Combined with the policy perspective, the trend of the pharmaceutical industry has maintained rigid demand and stable growth
    .
    In terms of policy, although pharmaceutical companies have faced many challenges in recent years due to factors such as the normalization of medicine and medical insurance fee control, they have also accelerated the pace of innovation, transformation, upgrading and standardized development, which is conducive to the high-quality development of
    the industry.
    Whether it is the 14th Five-Year Plan or a series of policies issued by relevant departments in recent years, they also support and encourage the pharmaceutical industry, among which with the advancement of new infrastructure and the landing of medical loan policies, the domestic medical equipment market demand is expected to explode, and accelerate the pace of domestic substitution, driving the development of
    the entire pharmaceutical market 。 From the perspective of industry prosperity and valuation, in terms of prosperity, many listed pharmaceutical companies have disclosed their 2022 performance forecasts, Huahai Pharmaceutical, Jincheng Pharmaceutical, Jardine Jiaye, Chuanning Biotechnology, Dongbao Biotechnology, Anke Biotechnology and many other pharmaceutical companies are expected to double their net profits in 2022, and Shanghai Yizhong is expected to increase the net profit attributable to shareholders of listed companies from January to December 2022 by 3852.
    72% ~ 4102.
    9% year-on-year, reaching 150 million yuan ~ 160 million yuan
    .
    It is reported that at present, more than seventy percent of pharmaceutical companies have a good annual performance
    .
    In addition, from the third quarter report of pharmaceutical companies in 2022, the third quarterly report of A-share pharmaceutical and biological listed companies has ended ((Shenwan industry classification, the same below)), in the first three quarters of 2022, the industry has achieved a total operating income of 1.
    82 trillion yuan, a year-on-year increase of 9.
    91%; The net profit attributable to the shareholders of the parent company was 195.
    925 billion yuan, a year-on-year increase of 8.
    14%.

    The overall performance of industry enterprises has increased, among which medical device companies have performed particularly well, with more than ninety percent achieving double growth
    in revenue and net profit.
    With the liberalization of policies, the recovery of consumption, and the intensification of aging, on the whole, the prosperity of the pharmaceutical industry will enter a good state
    .
    In terms of valuation, the valuation of the pharmaceutical sector is currently at a low level overall, and the research report released by Shanxi Securities recently mentioned that as of December 30, the overall valuation (TTM) of the Shenwan Pharmaceutical Index was 23.
    4 times, and the valuation, valuation premium rate, and historical ten-year quantile of the pharmaceutical sector were all at a relatively low level
    .
    Among them, the valuation level of medical services, medical devices, and biological products in the sub-sectors is low
    .
    In addition, for the pharmaceutical sector, in addition to CITIC Securities, many securities institutions have also expressed optimism about the pharmaceutical sector recently
    .
    For example, CICC said that it recommends investors to keep up with the rhythm of marginal changes in policy in the short term, and focus on three main lines in the medium term, one of which is medicine, the Internet, etc.
    ; CSC Securities recommends that investors continue to grasp the long window and pay attention to the ChiNext
    market, which has a more significant market win rate after the holiday.
    Among them, the direction where the fundamental expectation of significant improvement can be focused also includes medicine; Guotai Junan Securities suggests that investors focus on value and growth strategies, and can pay attention to tracks including pharmaceuticals; For example, GF Securities also recommends paying attention to medical equipment and vaccines with suitable valuations in the post-epidemic repair chain for the future market
    .
    These institutions are sending positive signals
    that the pharmaceutical sector has ushered in a layout opportunity.
    The industry expects that in the future, the allocation ratio
    of public fund pharmaceuticals will gradually increase within one or two years.
    From the perspective of returns, recently, pharmaceutical ETFs have also ushered in a sharp rise, including biotechnology ETFs, biomedical ETFs, and innovative drug ETFs, which have all soared, rising by 4.
    47%, 4.
    46% and 3.
    96%
    respectively.
    The industry expects that the current allocation of low-valued pharmaceutical industry ETF funds or pharmaceutical thematic funds may have a greater chance of making profits in the next few years, but investors also need to be reminded of investment risks
    .
    Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
    to anyone.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.